Reece Marillier

Bone Therapeutics — Belgium

Biochemistry, Genetics and Molecular Biology · Life Sciences

12h-index546citations53works2.12yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Adenosine and Purinergic Signaling(16), Immune Cell Function and Interaction(12), Tryptophan and brain disorders(11), T-cell and B-cell Immunology(9), Immunotherapy and Immune Responses(8)

Publications52 total

Inhibition of A2AR alleviates adenosine-mediated suppression of plasma cell differentiation
Frontiers in Immunology·2025Open Access
ENT1 inhibition enhances weight control and metabolic health in diet-induced obesity
Biomedicine & Pharmacotherapy·2025Open Access
A2AR-mediated inhibition of B cell maturation: a novel mechanism of immune suppression in cancer
2025Open Access
a-TIGIT mAb belrestotug in combination with anti-PD1 induces an immunocompetent tumor microenvironment (TME)
2025Open Access
Inhibition of ENT1 relieves intracellular adenosine-mediated T cell suppression in cancer
Nature Immunology·2025· 19 citedOpen Access
Abstract 3136: EOS-215, a first-in-class TREM2 antagonist, designed to reprogram the tumor microenvironment and overcome resistance
Cancer Research·2025· 2 cited
Abstract 5609: A novel PTPN1/2 inhibitor with high oral bioavailability enhances the antitumoral response
Cancer Research·2025
122P Intracellular adenosine drives profound lymphocyte suppression and can be reversed with EOS-984: A potent ENT1 antagonist
Immuno-Oncology Technology·2024Open Access
218P A novel tumor adenosine signature to guide indication selection for adenosine pathway inhibitors
Immuno-Oncology Technology·2024Open Access
48P The A2AR antagonist inupadenant promotes humoral responses in preclinical models
Immuno-Oncology Technology·2024Open Access
Abstract 734: Inhibition of equilibrative nucleoside transporter 1 relieves intracellular adenosine-mediated immune suppression
Cancer Research·2024· 2 cited
Abstract B032: Combined A2AR and PARP inhibition in homologous recombination deficient (HRD) castrate-resistant prostate cancer (CRPC)
Cancer Research·2023· 1 cited
Data from Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies
2023Open Access
Data from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
2023Open Access
Supplementary Data from Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies
2023Open Access
Table S2 from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
2023Open Access
Table S1, Table S3, Figures S1-S8 from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
2023Open Access
Supp Figures from Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies
2023Open Access
Data from Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies
2023Open Access
Table S2 from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Grégory Driessens(24), Erica Houthuys(21), Romain Pirson(20), João Marchante(20), Margreet Brouwer(19), Virginie Rabolli(17), Stefano Crosignani(16), Sofie Denies(16), Marie-Claire Letellier(12), Julie Preillon(12), Marjorie Mercier(12), Noémie Wald(11), Florence Nyawouame(11), Catherine Hoofd(11), Shruthi Prasad(10), Florence Lambolez(10), Chiara Martinoli(10), Yvonne McGrath(10), Sandra Cauwenberghs(9), Deepak Dalvie(9)